By Katherine Hamilton
Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.
The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.
Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.
Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.
The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.
Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.
Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 18, 2025 16:17 ET (20:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。